Characteristics | Events (n)/patients (n) | 3-year FFF rates - % [range] | 5-year FFF rates - % [range] | Log-rank test |
---|---|---|---|---|
p-value | ||||
Treatment | 0.0311* | |||
IG-IMRT | 3/49 | 95.87% [84.49%-98.95%] | 93.14% [79.96%-97.76%] | |
RP + IMRT | 9/49 | 87.61% [74.48%-94.24%] | 76.46% [58.31%-87.50%] | |
Age | ||||
≤ 66.8 years | 5/49 | 91.74% [79.47%-96.82%] | 88.35% [73.58%-95.12%] | 0.595 |
> 66.8 years | 7/49 | 91.59% [79.08%-96.76%] | 83.00% [67.17%-91.65%] | |
Tumor stage | ||||
T1 | 8/60 | 91.44% [80.61%-96.35%] | 84.37% [70.75%-91.99%] | 0.758 |
T2 | 4/38 | 92.11% [77.49%-97.38%] | 87.72% [69.57%-95.38%] | |
Gleason score | ||||
≤ 6 | 5/58 | 96.52% [86.80%-99.12%] | 89.15% [75.57%-95.40%] | 0.135 |
7 | 7/40 | 84.68% [68.98%-92.82%] | 81.29% [64.45%-90.69%] | |
Pretherapeutic PSA | ||||
≤ 8.7 ng/mL | 4/49 | 93.83% [82.08%-97.97%] | 90.99% [77.46%-96.57%] | 0.250 |
> 8.7 ng/mL | 8/49 | 89.55% [76.67%-95.52%] | 80.69% [64.58%-90.01%] | |
Concomitant ADT | ||||
No | 12/78 | 89.53% [80.13%-94.63%] | 82.02% [70.12%-89.52%] | 0.070 |
Yes | 0/20 | 100 [ND – ND] | 100 [ND – ND] | |
Adjuvant ADT | ||||
No | 12/84 | 90.29% [81.51%-95.03%] | 83.44% [72.36%-90.36%] | 0.156 |
Yes | 0/14 | 100 [ND – ND] | 100 [ND – ND] |